Log in

CNSX:CUREBiocure Technology Stock Price, Forecast & News

Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Volume44,500 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
Biocure Technology Inc. develops and commercializes biosimilar pharmaceutical products in South Korea. The company is developing Interferon Beta 1b for the treatment of multiple sclerosis; Ranibizumab, a monoclonal antibody fragment for the treatment of macular degeneration, as well as to treat a type of eye problem known as macular edema; and Filgrastim to treat neutropenia, a lack of white blood cells caused by cancer, bone marrow transplant, chemotherapy, or by other conditions. It is also developing a foot and mouth disease vaccine, a hair growth production product, and a breast cancer detection kit. Biocure Technology Inc. is headquartered in Vancouver, Canada.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.52 out of 5 stars

Industry, Sector and Symbol

Industry Biotechnology



Sales & Book Value

Annual SalesN/A



Next Earnings DateN/A

Receive CURE News and Ratings via Email

Sign-up to receive the latest news and ratings for CURE and its competitors with MarketBeat's FREE daily newsletter.

Biocure Technology (CNSX:CURE) Frequently Asked Questions

Has Biocure Technology been receiving favorable news coverage?

Headlines about CURE stock have been trending somewhat positive on Friday, InfoTrie Sentiment reports. The research group identifies positive and negative press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Biocure Technology earned a daily sentiment score of 1.6 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the next several days. View the latest news about Biocure Technology.

Who are some of Biocure Technology's key competitors?

What other stocks do shareholders of Biocure Technology own?

Who are Biocure Technology's key executives?

Biocure Technology's management team includes the following people:
  • Dr. Sang Mok Lee Ph.D., Pres, CEO & Director (Age 53)
  • Mr. Konstatin Lichtenwald, CFO & Director
  • Mr. Marco Nonni, Consultant

What is Biocure Technology's stock symbol?

Biocure Technology trades on the CNSX under the ticker symbol "CURE."

How do I buy shares of Biocure Technology?

Shares of CURE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Biocure Technology's official website?

The official website for Biocure Technology is www.biocuretech.com.

How can I contact Biocure Technology?

The company can be reached via phone at 604-609-7149.

This page was last updated on 7/3/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.